Polatuzumab Vedotin Induced CD20 Upregulation Contributes to the Efficacy of Mosunetuzumab in Combination With Polatuzumab Vedotin in Diffuse Large B‐Cell Lymphoma Preclinical Models
Authors
Mayu Tomita (ORCID: https://orcid.org/0000-0003-4348-6840)
Sei Shu (ORCID: https://orcid.org/0000-0001-9875-6989)
Polatuzumab Vedotin Induced CD20 Upregulation Contributes to the Efficacy of Mosunetuzumab in Combination With Polatuzumab Vedotin in Diffuse Large B‐Cell Lymphoma Preclinical Models
Mayu Tomita, Sei Shu, Natsumi Kawasaki, Shigeki Yoshiura et al.
Journal
eJHaem
Topics
CAR-T cell therapy research
article
Polatuzumab Vedotin Induced CD20 Upregulation Contributes to the Efficacy of Mosunetuzumab in Combination With Polatuzumab Vedotin in Diffuse Large B‐Cell Lymphoma Preclinical Models
Mayu Tomita, Sei Shu, Natsumi Kawasaki, Shigeki Yoshiura, Yoriko Yamashita‐Kashima, Xiaoxiao Liu